Potential approaches to reverse or repair renal fibrosis

Nature Reviews Nephrology

Volumn 10, Issue 4, 2014, Pages 226-237

  Tampe, Desiree ^a   Zeisberg, Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; AZACITIDINE; CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOSTATIN; ENDOTHELIN 1; GROWTH FACTOR; OSTEOGENIC PROTEIN 1; PHOSPHODIESTERASE INHIBITOR; PIRFENIDONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RENIN INHIBITOR; SIMTUZUMAB; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMSTATIN;

APOPTOSIS; CAPILLARY FLOW; CELL ACTIVATION; CELL INTERACTION; CELL TRANSFORMATION; CHRONIC KIDNEY DISEASE; CPG ISLAND; DISEASE SEVERITY; DNA METHYLATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIUM CELL; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; HISTONE MODIFICATION; HOMEOSTASIS; HYPOXIA; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY TUBULE EPITHELIUM; MICROCIRCULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; RENAL PROTECTION; REVIEW; THROMBOCYTE ACTIVATION; TUBULAR EPITHELIAL CELL; VASOCONSTRICTION;

ANTI-INFLAMMATORY AGENTS; BONE MORPHOGENETIC PROTEIN 7; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE PROGRESSION; ENDOTHELIN-1; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MICROCIRCULATION; PHOSPHODIESTERASE INHIBITORS; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84897107588     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.14     Document Type: Review

References (185)

1. Ahlmn, J. Incidence of chronic renal insufficiency. A study of the incidence and pattern of renal insufficiency in adults during 1966-1971 in Gothenburg. Acta Med. Scand. Suppl. 582, 1-50 (1975
2. Rutherford, W. E., Blondin, J., Miller, J. P., Greenwalt, A. S. & Vavra, J. D. Chronic progressive renal disease: Rate of change of serum creatinine concentration. Kidney Int. 11, 62-70 (1977
3. Leumann, E. P. Progression of renal insufficiency in pediatric patients: Estimation from serum creatinine. Helv. Paediatr. Acta 33, 25-35 (1978
4. Drawz, P. E., Goswami, P., Azem, R., Babineau, D. C. & Rahman, M. A simple tool to predict end-stage renal disease within 1 year in elderly adults with advanced chronic kidney disease. J. Am. Geriatr. Soc. 61, 762-768 (2013
5. McLaughlin, M. J. & Courtney, A. E. Early recognition of CKD can delay progression. Practitioner 257, 13-17 (2013
6. Whaley-Connell, A. T., Tamura, M. K., Jurkovitz, C. T., Kosiborod, M. & McCullough, P. A. Advances in CKD detection and determination of prognosis: Executive summary of the National Kidney Foundation-Kidney Early Evaluation Program (KEEP) 2012 annual data report. Am. J. Kidney Dis. 61, S1-S3 (2013
7. Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C. & Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation, N. Engl. J. Med. 339, 69-75 (1998
8. Fioretto, P., Sutherland, D. E., Najafian, B. & Mauer, M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int. 69, 907-912 (2006
9. Remuzzi, A. et al. Regression of diabetic complications by islet transplantation in the rat. Diabetologia 52, 2653-2661 (2009
10. Risdon, R. A., Sloper, J. C. & De Wardener, H. E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2, 363-366 (1968
11. Bohle, A., Glomb, D., Grund, K. E. & Mackensen, S. Correlation between relative interstitial volume of the renal cortex and serum creatinine concentration in minimal changes with nephrotic syndrome and in focal sclerosing glomerulonephritis. Virchows Arch. A Pathol. Anat. Histol. 376, 221-232 (1977
12. Zeisberg, M. & Kalluri, R. Cellular mechanisms of tissue fibrosis. Common and organ-specific mechanisms associated with tissue fibrosis. Am. J. Physiol. Cell Physiol. 304, C216-C225 (2013
13. Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 18, 1028-1040 (2012
14. Zeisberg, M. & Neilson, E. G. Mechanisms of tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 21, 1819-1834 (2010
15. Aydin, S. et al. Influence of microvascular endothelial cells on transcriptional regulation of proximal tubular epithelial cells. Am. J. Physiol. Cell Physiol. 294, C543-C554 (2008
16. Eddy, A. A. Molecular insights into renal interstitial fibrosis. J. Am. Soc. Nephrol. 7, 2495-2508 (1996
17. Kim, H. et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 12, 736-748 (2001
18. Yang, J. et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J. Clin. Invest. 110, 1525-1538 (2002
19. Zeisberg, M. et al. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease, PLoS Med. 3, e100 (2006
20. Zeisberg, M. et al. BMP-7 counteracts TGF-1-induced epithelial-to- mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968 (2003
21. Zeisberg, M. et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. 285, F1060-F1067 (2003
22. Iredale, J. P. et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 102, 538-549 (1998
23. Fallowfield, J. A. & Iredale, J. P. Reversal of liver fibrosis and cirrhosis-an emerging reality. Scott. Med. J. 49, 3-6 (2004
24. Schuppan, D., Ruehl, M., Somasundaram, R. & Hahn, E. G. Matrix as a modulator of hepatic fibrogenesis, Semin. Liver Dis. 21, 351-372 (2001
25. Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009-1017 (2010
26. Zeisberg, M., Strutz, F. & Mller, G. A. Role of fibroblast activation in inducing interstitial fibrosis. J. Nephrol. 13 (Suppl. 3), S111-S120 (2000
27. Harris, R. C. & Neilson, E. G. Toward a unified theory of renal progression. Annu. Rev. Med. 57, 365-380 (2006
28. Rodemann, H. P. & Mller, G. A. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am. J. Kidney Dis. 17, 684-686 (1991
29. Bechtel, W. et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16, 544-550 (2010
30. LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053 (2013
31. Iwano, M. et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341-350 (2002
32. Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97 (2010
33. Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M. & Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282-2287 (2008
34. Roberts, A. B. et al. Transforming growth factor type : Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA 83, 4167-4171 (1986
35. Richeldi, L. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365, 1079-1087 (2011
36. Frazier, K., Williams, S., Kothapalli, D., Klapper, H. & Grotendorst, G. R. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J. Invest. Dermatol. 107, 404-411 (1996
37. Igarashi, A. et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J. Invest. Dermatol. 106, 729-733 (1996
38. Iwano, M. et al. Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol. Ther. 3, 149-159 (2001
39. Hodgkins, K. S. & Schnaper, H. W. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr. Nephrol. 27, 901-909 (2012
40. Nangaku, M. Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure. Intern. Med. 43, 9-17 (2004
41. Zeisberg, M. & Neilson, E. G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119, 1429-1437 (2009
42. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01791855 (2013
43. Witek, R. P. et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50, 1421-1430 (2009
44. Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. V. & Bonventre, J. V. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 16, 535-543 (2010
45. Bussolati, B. et al. Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166, 545-555 (2005
46. Maeshima, A., Yamashita, S. & Nojima, Y. Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. J. Am. Soc. Nephrol. 14, 3138-3146 (2003
47. Smeets, B. et al. Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. J. Pathol. 229, 645-659 (2013
48. Kang, D. H. et al. Role of the microvascular endothelium in progressive renal disease. J. Am. Soc. Nephrol. 13, 806-816 (2002
49. Matsumoto, M. et al. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J. Am. Soc. Nephrol. 15, 1574-1581 (2004
50. Zoccali, C. Endothelial dysfunction in CKD: A new player in town Nephrol. Dial. Transplant. 23, 783-785 (2008
51. Maric-Bilkan, C., Flynn, E. R. & Chade, A. R. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. Am. J. Physiol. Renal Physiol. 302, F308-F315 (2012
52. Chade, A. R. et al. Beneficial effects of antioxidant vitamins on the stenotic kidney. Hypertension 42, 605-612 (2003
53. Pillebout, E. et al. Proliferation and remodeling of the peritubular microcirculation after nephron reduction: Association with the progression of renal lesions. Am. J. Pathol. 159, 547-560 (2001
54. Ohashi, R. et al. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J. Am. Soc. Nephrol. 13, 1795-1805 (2002
55. Clements, M. E., Chaber, C. J., Ledbetter, S. R. & Zuk, A. Increased cellular senescence and vascular rarefaction exacerbate the progression of kidney fibrosis in aged mice following transient ischemic injury. PLoS ONE 8, e70464 (2013
56. Renkonen, R., Turunen, J. P., Rapola, J. & Hyry, P. Characterization of high endothelial-like properties of peritubular capillary endothelium during acute renal allograft rejection. Am. J. Pathol. 137, 643-651 (1990
57. Chade, A. R. & Kelsen, S. Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: A novel potential therapeutic approach. Am. J. Physiol. Renal Physiol. 302, F1342-F1350 (2012
58. Sun, D. et al. Thrombospondin-1 short hairpin RNA suppresses tubulointerstitial fibrosis in the kidney of ureteral obstruction by ameliorating peritubular capillary injury. Kidney Blood Press. Res. 35, 35-47 (2012
59. Yamamoto, Y. et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53, 1831-1840 (2004
60. Ichinose, K. et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54, 2891-2903 (2005
61. Chade, A. R. Renovascular disease, microcirculation, and the progression of renal injury: Role of angiogenesis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, R783-R790 (2011
62. Pergola, P. E. et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am. J. Nephrol. 33, 469-476 (2011
63. Lagaaij, E. L. et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 357, 33-37 (2001
64. Grimm, P. C. et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N. Engl. J. Med. 345, 93-97 (2001
65. Fadini, G. P., Losordo, D. & Dimmeler, S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ. Res. 110, 624-637 (2012
66. Kurts, C., Panzer, U., Anders, H. J. & Rees, A. J. The immune system and kidney disease: Basic concepts and clinical implications. Nat. Rev. Immunol. 13, 738-753 (2013
67. Anders, H. J. et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J. Am. Soc. Nephrol. 15, 1504-1513 (2004
68. Ricardo, S. D., van Goor, H. & Eddy, A. A. Macrophage diversity in renal injury and repair. J. Clin. Invest. 118, 3522-3530 (2008
69. Franois, A. et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res. Ther. 15, R168 (2013
70. Huaux, F. et al. Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J. Immunol. 171, 5470-5481 (2003
71. Lebleu, V. S., Sugimoto, H., Miller, C. A., Gattone, V. H. 2nd & Kalluri, R. Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease, Lab. Invest. 88, 284-292 (2008
72. Kaviratne, M. et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF- independent. J. Immunol. 173, 4020-4029 (2004
73. Elger, M. et al. Nephrogenesis is induced by partial nephrectomy in the elasmobranch Leucoraja erinacea. J. Am. Soc. Nephrol. 14, 1506-1518 (2003
74. Little, M. H. Regrow or repair: Potential regenerative therapies for the kidney. J. Am. Soc. Nephrol. 17, 2390-2401 (2006
75. Lindoso, R. S., Verdoorn, K. S. & Einicker-Lamas, M. Renal recovery after injury: The role of Pax-2. Nephrol. Dial. Transplant. 24, 2628-2633 (2009
76. Narlis, M., Grote, D., Gaitan, Y., Boualia, S. K. & Bouchard, M. Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney, J. Am. Soc. Nephrol. 18, 1121-1129 (2007
77. Park, J. S., Valerius, M. T. & McMahon, A. P. Wnt/-catenin signaling regulates nephron induction during mouse kidney development. Development 134, 2533-2539 (2007
78. Bramlage, C. P. et al. Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. BMC Nephrol. 11, 31 (2010
79. Dudley, A. T., Lyons, K. M. & Robertson, E. J. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev. 9, 2795-2807 (1995
80. Vukicevic, S. et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J. Clin. Invest. 102, 202-214 (1998
81. Sugimoto, H., Grahovac, G., Zeisberg, M. & Kalluri, R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56, 1825-1833 (2007
82. Morrissey, J. et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J. Am. Soc. Nephrol. 13 (Suppl. 1), S14-S21 (2002
83. Zeisberg, M., Shah, A. A. & Kalluri, R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 280, 8094-8100 (2005
84. Swencki-Underwood, B. et al. Expression and characterization of a human BMP-7 variant with improved biochemical properties. Protein Expr. Purif. 57, 312-319 (2008
85. Sugimoto, H. et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. 18, 396-404 (2012
86. Bachmann, S., Kriz, W., Kuhn, C. & Franke, W. W. Differentiation of cell types in the mammalian kidney by immunofluorescence microscopy using antibodies to intermediate filament proteins and desmoplakins. Histochemistry 77, 365-394 (1983
87. Ebrahimi, B. et al. Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. PLoS ONE 8, e67474 (2013
88. Ebrahimi, B. et al. Addition of endothelial progenitor cells to renal revascularization restores medullary tubular oxygen consumption in swine renal artery stenosis. Am. J. Physiol. Renal Physiol. 302, F1478-F1485 (2012
89. Reinders, M. E. et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: Results of a phase I study. Stem Cells Transl. Med. 2, 107-111 (2013
90. Tan, J. et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 307, 1169-1177 (2012
91. Didi, M. et al. Parthenogenetic stem cells for tissue-engineered heart repair. J. Clin. Invest. 123, 1285-1298 (2013
92. Bhutani, N., Burns, D. M. & Blau, H. M. DNA demethylation dynamics. Cell 146, 866-872 (2011
93. Van Beneden, K. et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicol. Appl. Pharmacol. 271, 276-284 (2013
94. Manson, S. R., Song, J. B., Hruska, K. A. & Austin, P. F. HDAC dependent transcriptional repression of Bmp-7 potentiates TGF- mediated renal fibrosis in obstructive uropathy. J. Urol. 191, 242-252 (2013
95. Reddy, M. A. et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int. http://dx.doi.org/10.1038/ ki.2013.387 (2013
96. Tampe, B. et al. Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis. J. Am. Soc. Nephrol. (in press
97. Kolfschoten, I. G. et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121, 849-858 (2005
98. Suzuki, T. & Miyata, N. Non-hydroxamate histone deacetylase inhibitors. Curr. Med. Chem. 12, 2867-2880 (2005
99. Israili, Z. H. et al. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res. 36, 1453-1461 (1976
100. Chen, J. et al. The metabolic syndrome and chronic kidney disease in US adults. Ann. Intern. Med. 140, 167-174 (2004
101. Molnar, M. Z. et al. ACE inhibitor and angiotensin receptor blocker use and mortality in patients with chronic kidney disease. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.10.050 (2013
102. Kilbride, H. S. et al. Accuracy of the MDRD (modification of diet in renal disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am. J. Kidney Dis. 61, 57-66 (2013
103. Stengel, B. et al. The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gft388 (2013
104. Gabbai, F. B. et al. Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin. J. Am. Soc. Nephrol. 7, 1770-1776 (2012
105. Kanasaki, M., Nagai, T., Kitada, M., Koya, D. & Kanasaki, K. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: A blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair 4, 25 (2011
106. Collins, A. J. et al. US Renal Data System Annual Data Report. Am. J. Kidney Dis. 59 (Suppl. 1), evii (2011
107. Zeisberg, M. & Mller, G. A. Mechanistic insights into the antifibrotic activity of aliskiren in the kidney, Hypertens. Res. 35, 266-268 (2012
108. Nguyen, G. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002
109. Feldman, D. L. et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52, 130-136 (2008
110. Messerli, F. H. & Bangalore, S. ALTITUDE trial and dual RAS blockade: The alluring but soft science of the surrogate end point. Am. J. Med. 126, e1-e3 (2013
111. Lecaire, T. J., Klein, B. E., Howard, K. P., Lee, K. E. & Klein, R. Risk for end-stage renal isease over 25 years in the population-based WESDR cohort. Diabetes Care 37, 381-388 (2013
112. Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B. & Ruoslahti, E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor 1. Nature 346, 371-374 (1990
113. Border, W. A. et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360, 361-364 (1992
114. Isaka, Y. et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. 2, 418-423 (1996
115. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00464321 (2010
116. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01113801 (2013
117. Garber, K. Companies waver in efforts to target transforming growth factor in cancer. J. Natl Cancer Inst. 101, 1664-1667 (2009
118. Akhurst, R. J. TGF- antagonists: why suppress a tumor suppressor J. Clin. Invest. 109, 1533-1536 (2002
119. Massagu, J. How cells read TGF- signals. Nat. Rev. Mol. Cell Biol. 1, 169-178 (2000
120. Zeisberg, M. et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347 (2007
121. Hruska, K. A. et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am. J. Physiol. Renal Physiol. 279, F130-F143 (2000
122. Wang, S. & Hirschberg, R. BMP7 antagonizes TGF-dependent fibrogenesis in mesangial cells. Am. J. Physiol. Renal Physiol. 284, F1006-F1013 (2003
123. Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952-961 (2007
124. Flier, S. N. et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J. Biol. Chem. 285, 20202-20212 (2010
125. Bradham, D. M., Igarashi, A., Potter, R. L. & Grotendorst, G. R. Connective tissue growth factor: A cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J. Cell Biol. 114, 1285-1294 (1991
126. Nguyen, T. Q. et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 31, 1177-1182 (2008
127. Yokoi, H. et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15, 1430-1440 (2004
128. Guha, M., Xu, Z. G., Tung, D., Lanting, L. & Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 21, 3355-3368 (2007
129. Adler, S. G. et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5, 1420-1428 (2010
130. Taniguchi, H. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35, 821-829 (2010
131. Shimizu, T. et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 54, 99-109 (1998
132. Ziyadeh, F. N. et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor- antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA 97, 8015-8020 (2000
133. RamachandraRao, S. P. et al. Pirfenidone is renoprotective in diabetic kidney disease. J. Am. Soc. Nephrol. 20, 1765-1775 (2009
134. Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R. & Kopp, J. B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2, 906-913 (2007
135. Sharma, K. et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144-1151 (2011
136. Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621 (2006
137. Sarvaiya, P. J., Guo, D., Ulasov, I., Gabikian, P. & Lesniak, M. S. Chemokines in tumor progression and metastasis. Oncotarget 4, 2171-2185 (2013
138. Anders, H. J., Vielhauer, V. & Schlondorff, D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 63, 401-415 (2003
139. Reich, B. et al. Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int. 84, 78-89 (2013
140. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01447147 (2013
141. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01440257 (2013
142. Sullivan, T. et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am. J. Physiol. Renal Physiol. 305, F1288-F1297 (2013
143. Hanefeld, M. et al. Orally-administered chemokine receptor CCR2 antagonist CCX140-B in type 2 diabetes: A pilot double-blind, randomized clinical trial. J. Diabetes Metab. 3, 225 (2012
144. Inoue, A. et al. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J. Biol. Chem. 264, 14954-14959 (1989
145. Arinami, T. et al. Chromosomal assignments of the human endothelin family genes: The endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am. J. Hum. Genet. 48, 990-996 (1991
146. Karet, F. E. Endothelin peptides and receptors in human kidney, Clin. Sci. (Lond.) 91, 267-273 (1996
147. Dhaun, N., Goddard, J. & Webb, D. J. The endothelin system and its antagonism in chronic kidney disease J. Am. Soc. Nephrol. 17, 943-955 (2006
148. Attin, T., Camidge, R., Newby, D. E. & Webb, D. J. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91, 825-831 (2005
149. Wesson, D. E., Simoni, J. & Green, D. F. Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular endothelial cells. J. Clin. Invest. 101, 578-583 (1998
150. Hocher, B. & Paul, M. Transgenic animal models for the analysis of the renal endothelin system. Nephrol. Dial. Transplant. 15, 935-937 (2000
151. Saito, Y. et al. Application of monoclonal antibodies for endothelin to hypertensive research. Hypertension 15, 734-738 (1990
152. Kuc, R. & Davenport, A. P. Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J. Cardiovasc. Pharmacol. 44 (Suppl. 1), S224-S226 (2004
153. Benigni, A. et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 44, 440-444 (1993
154. Opocensk, M. et al. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 48, 965-971 (2006
155. Boffa, J. J., Tharaux, P. L., Dussaule, J. C. & Chatziantoniou, C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37, 490-496 (2001
156. Gmez-Garre, D. et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 27, 885-892 (1996
157. Fukuda, K. et al. Role of endothelin as a mitogen in experimental glomerulonephritis in rats, Kidney Int. 49, 1320-1329 (1996
158. Benigni, A. et al. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. 54, 353-359 (1998
159. Saleh, M. A., Pollock, J. S. & Pollock, D. M. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J. Pharmacol. Exp. Ther. 338, 263-270 (2011
160. Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655-664 (2009
161. Mann, J. F. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527-535 (2010
162. Chen, Y. M., Wu, K. D., Tsai, T. J. & Hsieh, B. S. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-stimulated collagen synthesis by vascular smooth muscle cells. J. Mol. Cell Cardiol. 31, 773-783 (1999
163. Strutz, F. et al. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol. Dial. Transplant. 15, 1535-1546 (2000
164. Lin, S. L. et al. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 13, 2916-2929 (2002
165. Rodriguez-Morn, M. et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: A double-blind, placebo-controlled randomized trial. Clin. Nephrol. 66, 3-10 (2006
166. Perkins, R. M. et al. Effect of pentoxifylline on GFR decline in CKD: A pilot, double-blind, randomized, placebo-controlled trial. Am. J. Kidney Dis. 53, 606-616 (2009
167. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01377285 (2013
168. Zalba, G. et al. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction Nephrol. Dial. Transplant. 16 (Suppl. 1), 2-5 (2001
169. Firoozi, F., Longhurst, P. A. & White, M. D. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. BJU Int. 96, 164-168 (2005
170. Dousa, T. P. Cyclic-3,5-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 55, 29-62 (1999
171. Lau, D. H., Mikhailidis, D. P. & Thompson, C. S. The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: A pilot study. In Vivo 21, 851-854 (2007
172. Jeong, K. H. et al. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am. J. Nephrol. 29, 274-282 (2009
173. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01200394 (2013
174. Wilcox, C. S. Reactive oxygen species: Roles in blood pressure and kidney function. Curr. Hypertens. Rep. 4, 160-166 (2002
175. Touyz, R. M. Reactive oxygen species in vascular biology: Role in arterial hypertension. Expert Rev. Cardiovasc. Ther. 1, 91-106 (2003
176. Vaziri, N. D. & Rodriguez-Iturbe, B. Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2, 582-593 (2006
177. Mueller, C. F., Laude, K., McNally, J. S. & Harrison, D. G. ATVB in focus: Redox mechanisms in blood vessels, Arterioscler. Thromb. Vasc. Biol. 25, 274-278 (2005
178. Griendling, K. K. NADPH oxidases: New regulators of old functions. Antioxid. Redox Signal. 8, 1443-1445 (2006
179. Lassegue, B. & Clempus, R. E. Vascular NAD(P)H oxidases: Specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R277-R297 (2003
180. Rajagopalan, S. et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923 (1996
181. Virdis, A., Neves, M. F., Amiri, F., Touyz, R. M. & Schiffrin, E. L. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J. Hypertens. 22, 535-542 (2004
182. Aoyama, T. et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56, 2316-2327 (2012
183. Fortuo, A. et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J. Hypertens. 22, 2169-2175 (2004
184. Higashi, Y. et al. Endothelial function and oxidative stress in renovascular hypertension. N. Engl. J. Med. 346, 1954-1962 (2002
185. Lip, G. Y. et al. Oxidative stress in malignant and non-malignant phase hypertension. J. Hum. Hypertens. 16, 333-336 (2002